Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging
Peking Union Medical College Hospital
60 participants
Sep 1, 2025
INTERVENTIONAL
Conditions
Summary
Primary Sjögren's syndrome (pSS) is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration, progressive destruction of salivary gland acini, and varying degrees of functional impairment and fibrosis. Conventional imaging provides limited ability to simultaneously evaluate glandular function and inflammatory activity, leading to challenges in disease staging and treatment decision-making. This study explores a conceptual dual-tracer imaging framework using PSMA PET and FAPI PET to delineate complementary biological processes in pSS.
Eligibility
Inclusion Criteria2
- Age 18-80 years;
- Fulfillment of the 2016 ACR-EULAR Classification Criteria for pSS at enrollment. OR diagnosis of a solid tumor scheduled for FAPI PET imaging
Exclusion Criteria3
- Combined with tumors or other connective tissue diseases (for SS group);
- Patients who are currently using hormones/biological agents (for both groups)；
- Pregnancy or lactation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PSMA PET imaging performed for clinical evaluation in prostate cancer patients, used as a comparator for physiologic salivary gland PSMA uptake.
FAPI PET imaging to assess inflammatory activity (FAPI) in patients with primary Sjögren's syndrome.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07324733